Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients: Results From the Vienna CAT-BLED Study.

ABSTRACT:

Background

The hemostatic system is tightly interconnected with cancer. Research has focused predominantly on thrombotic complications, but less is known about bleeding and bleeding risk prediction. Growth differentiation factor (GDF)-15 has previously emerged as a prognostic biomarker for bleeding.

Objectives

The aim of this study was to investigate the association and predictive ability of GDF-15 for bleeding risk in patients with cancer.

Methods

The CAT-BLED (Vienna Cancer, Thrombosis, and Bleeding) study is a prospective, observational cohort study including cancer patients initiating systemic anticancer therapies. Patients were followed for up to 2 years for thrombotic and bleeding events. The primary outcome was major bleeding. GDF-15 was measured at inclusion a

SUBMITTER: Englisch C 

PROVIDER: S-EPMC11866448 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature